Mitochondria as disease-relevant organelles in rheumatoid arthritis
Mitochondria in RA macrophages. Synovial tissue Mφ (STM) are a highly heterogeneous population in terms of mitochondrial activity, metabolic networks, and functional commitment. MERTKhi pro-resolving STM are committed to highly active oxidative phosphorylation (OXPHOS), based on the elevated expression of mitochondria-encoded ETC subunit genes. Conversely, pro-inflammatory STM, which mostly lack MERTK, upregulate glucose and lactate transporters and rely more on glycolysis and the pentose phosphate pathway for energy supply. Pro-inflammatory Mφ upregulate the glycolytic enzyme pyruvate kinase M2 (PKM2) to feed pyruvate into the mitochondria, generate ample ATP as well as ROS. PKM2 is sensitive to ROS-imposed structural changes and transitions into the nucleus to function as a driver of pro-inflammatory cytokines and tissue-injurious enzymes. Hyperactive mitochondria form membrane interaction sites with the ER, so-called MAMs, that support calcium exchange, sustaining high metabolic and functional activity of RA Mφ. Mφ that are functionally active in the synovial tissue environment need to be able to adapt to the harsh conditions of the tissue niche: a hypoxic, glucose deplete microenvironment. RA Mφ adjust to the bioenergetic conditions in synovial tissue by upregulating the transcription factor RFX5. RFX5 target genes include the enzyme glutamate dehydrogenase 1 (GLUD1), which allows the cells to metabolize glutamate into alpha-ketoglutarate and fuel the TCA cycle. In parallel, RFX5 controls the density of HLA-DR molecules on the cell surface, guiding the cells’ antigen-presenting function. RFX5 is induced by the small cytokine CCL18 and functions as a potent coordinator of antigen-presenting capabilities and successful survival in a glucose deplete environment